A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
The majority of clinical trials included a thoroughly selected population of patients predominantly with clear-cell renal cell carcinoma (RCC), without brain metastases and with a good somatic status. Due to the fact that in routine practice, the patient population is more heterogeneous (patients with non-clear cell RCC, brain metastases, and an ECOG somatic status of > 1, the questions arise of whether it is effective and expedient to use target drugs in this group of patients. The results ofdoaj:26e4338dc2774006b8c6379e342c7a19 fatcat:523qplzuzjfi5ayimz3qe5tog4